US mulls equity stakes in chipmakers receiving CHIPS Act Funds - Reuters
Today, Glaukos Corporation (NYSE:GKOS), a $5.4 billion market cap healthcare company with impressive 24% year-over-year revenue growth, disclosed the outcomes of its annual stockholders’ meeting held on May 29, 2025. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 6.49 and operates with moderate debt levels. The meeting included three key proposals, all of which were detailed in the company’s definitive proxy statement filed with the Securities and Exchange Commission on April 15, 2025.
The first proposal involved the election of three Class I directors to serve until the 2028 annual meeting. Mark J. Foley received 38,866,634 votes in favor, with 11,305,858 votes withheld. David F. Hoffmeister garnered 46,794,939 votes in favor, alongside 3,377,553 withheld votes. Gilbert H. Kliman, M.D. secured 42,495,145 votes in favor, with 7,677,347 votes withheld. In each case, there were 3,221,029 broker non-votes.
The second proposal was a non-binding advisory vote on the compensation of the company’s named executive officers. This proposal received 48,971,169 votes in favor, 1,143,789 votes against, and 57,534 abstentions, with 3,221,029 broker non-votes.
The third proposal sought the ratification of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. This proposal was approved with 53,222,095 votes in favor, 140,642 votes against, and 30,784 abstentions. There were no broker non-votes for this proposal.
This information is based on a press release statement from Glaukos Corporation. InvestingPro analysis indicates the stock is currently trading above its Fair Value, with 8 analysts recently revising earnings estimates downward. Discover comprehensive insights and 5 additional ProTips in the detailed Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Glaukos Corporation reported a first-quarter 2025 earnings per share (EPS) of -0.22, surpassing the forecasted -0.35. The company’s consolidated net sales reached $106.7 million, marking a 25% increase year-over-year, with the U.S. glaucoma franchise achieving record net sales of $59.1 million, a 41% increase. Despite these positive results, Glaukos’ stock experienced a decline in aftermarket trading, reflecting investor caution. Stephens, Needham, and JPMorgan have all adjusted their price targets for Glaukos, citing various factors affecting the company’s outlook. Stephens lowered its target to $115 while maintaining an Overweight rating, citing challenges in the U.S. glaucoma market. Needham also set a new target of $115 and maintained a Buy rating, noting an increase in projected iDose contributions. JPMorgan reduced its target to $100, highlighting a slower-than-expected growth in iDose sales. Analysts are closely monitoring the company’s progress, especially the anticipated FDA decision on iDose re-treatment by the end of 2025, which could significantly impact Glaukos’ future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.